A
AZmed
The first French company to commercialize an AI-powered radiology software
About AZmed
AZmed is a healthcare technology company specializing in artificial intelligence (AI) solutions for medical diagnostics. The company's flagship product, Rayvolve, is an AI diagnostic tool designed to detect fractures on standard X-rays. This tool has received clearance from the U.S. Food and Drug Administration (FDA), underscoring its reliability and effectiveness. Rayvolve aims to assist doctors by saving time and increasing the accuracy of diagnoses, particularly in emergency room settings where quick and precise assessments are crucial.
Read full description
AZmed primarily serves hospitals, emergency departments, and radiology units, providing them with advanced diagnostic capabilities. The company operates in the healthcare technology market, focusing on AI-driven innovations to improve patient care. Its business model revolves around selling and licensing its software to medical institutions, generating revenue through subscription fees and service contracts.
By integrating Rayvolve into existing medical imaging systems, AZmed ensures that its solution is easily accessible to radiologists and emergency physicians. The software's predictions are available within minutes and can be reviewed alongside the original X-ray images, helping to ensure that no fractures go unnoticed, regardless of the time or urgency of the situation.
At a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- Paris, France
- Employees
- 105
- Open positions
- 1
- Dealroom signal
- 76.4/100
- Industry
- Health
- Sub-industry
- Medical Devices, Health Platform
- Sector
- Health Tech & Medtech, CRM, X-Ray, Medical Imaging, Core AI, Tech for Hospitals and Clinics, Clinical Decision Support, Tech for Medical Professionals
- Technology
- Artificial Intelligence, Deep Tech
- Business model
- SaaS
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Feb 2024 | $17M | $66M | Teampact Ventures · Techstars · Maison Worms | ↗ |
| SEED✓Equity / VC | Oct 2021 | $1.1M | $6.6M | Future Investment Initiative - FII | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for AZmed is 9.6K monthly website visits, up 7.9% over the last three months. AZmed's team grew 5% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Techstars
Angelsquare
Future Investment Initiative - FII
Series A2 investors entered at this stage
Teampact Ventures
Maison Worms
Other known investors3 additional known investors
EIT Health
Albo Club
Riyadh Techstars Accelerator
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about AZmed on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AZmed’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.